Vestal Point Capital LP Buys 2,685,000 Shares of Savara Inc (NASDAQ:SVRA)

Vestal Point Capital LP grew its stake in Savara Inc (NASDAQ:SVRA - Free Report) by 33.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,775,000 shares of the company's stock after purchasing an additional 2,685,000 shares during the period. Savara comprises about 2.0% of Vestal Point Capital LP's investment portfolio, making the stock its 20th biggest position. Vestal Point Capital LP owned about 6.28% of Savara worth $33,079,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cibc World Markets Corp acquired a new stake in Savara in the 4th quarter worth $33,000. XTX Topco Ltd acquired a new stake in shares of Savara during the 4th quarter valued at about $34,000. Ameriprise Financial Inc. acquired a new stake in shares of Savara during the 4th quarter valued at about $37,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara during the 4th quarter valued at about $41,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Savara during the 4th quarter valued at about $48,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 target price on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Savara presently has an average rating of "Moderate Buy" and an average price target of $8.83.

Savara Price Performance

SVRA stock traded down $0.09 during trading on Friday, hitting $2.84. 716,088 shares of the stock traded hands, compared to its average volume of 1,303,176. Savara Inc has a one year low of $2.26 and a one year high of $5.11. The stock has a market cap of $490.86 million, a price-to-earnings ratio of -6.60 and a beta of 0.44. The company has a 50 day simple moving average of $2.97 and a 200 day simple moving average of $3.00. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Equities analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.